The ability of BRAF inhibitors (and MEK inhibitors) to modify the tumour microenvironment and enhance anti-tumour immune responses in BRAF-mutated melanoma supports the idea that a combination of targeted therapy and immunotherapy could provide greater anti-tumour activity. This evidence concerns the gene MAP2K7 and melanoma.